Recent Company News

• 07:35 AM ET Mar 05, 2026
  

  Silence Therapeutics reports FY EPS ($0.63) vs FactSet ($0.91) [6 est, ($2.11)-(0.52)] ($5.78, 0.00)

• 02:00 PM ET Mar 02, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 23-Feb

• 07:37 AM ET Dec 22, 2025
  

  Silence Therapeutics discloses on 18-Dec it appointed CFO Rhonda Hellums to the board, effectively immediately - 8-K ($6.37, 0.00)

• 08:14 AM ET Dec 15, 2025
  

  Silence Therapeutics CEO Craig Tooman to end employment; effective 14-Dec ($6.32, 0.00)

• 11:28 AM ET Dec 04, 2025
  

  StreetAccount Summary - US unusual volume traders

• 06:43 AM ET Nov 20, 2025
  

  Transcript Intelligence: Silence Therapeutics at Jefferies Global Healthcare Conference

• 07:40 AM ET Nov 06, 2025
  

  Silence Therapeutics reports Q3 EPS ($0.15) vs FactSet ($0.19) [5 est, ($0.40)-(0.09)] ($6.24, 0.00)

• 08:26 AM ET Oct 27, 2025
  

  StreetAccount Summary - US Pre-market trading

• 07:32 AM ET Oct 23, 2025
  

  Silence Therapeutics completes enrollment in SANRECO Ph 2 study of divesiran for polycythemia vera (PV) ($7.20, 0.00)

• 07:42 AM ET Aug 07, 2025
  

  Silence Therapeutics reports Q2 EPS ($0.19) vs FactSet ($0.13) [4 est, ($0.18)-(0.09)] ($5.32, 0.00)